Article Text

Download PDFPDF
Rofecoxib increased risk of CV events in patients with history of colorectal adenomas ⩾1 year after stopping treatment

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Source of funding: Merck Research Laboratories.